Discovery and characterization of natural product luteolin as an effective inhibitor of human pyridoxal kinase

• Published in: Bioorganic chemistry 2024-02, Vol.143, p.107057-107057, Article 107057
• Main Authors: Zhu, Yunmei, Bao, Guangsen, Zhu, Gaolin, Zhang, Kai, Zhu, Sanyong, Hu, Junchi, He, Jia, Jiang, Wei, Fan, Jianjun, Dang, Yongjun
• Format: Article
• Language: English
• Subjects: High-throughput screening; Leukemia cell; Luteolin; Protein crystal structure; Pyridoxal kinase
• ISSN: 0045-2068; 1090-2120
• DOI: 10.1016/j.bioorg.2023.107057

[Display omitted] •The high-throughput screening strategy yields effective PDXK inhibitors.•Luteolin is a reversible ATP-competitive inhibitor of PDXK.•Luteolin exerts anti-proliferative activity by reducing PLP levels in AML cells. Pyridoxal kinase (PDXK) is an essential enzyme in the synthesis of pyridoxal 5-phosphate (PLP), the active form of vitamin B6, which plays a pivotal role in maintaining the enzyme activity necessary for cell metabolism. Thus, PDXK has garnered attention as a potential target for metabolism regulation and tumor therapy. Despite this interest, existing PDXK inhibitors have faced limitations, including weak suppressive activity, unclear mechanisms of action, and associated toxic side effects. In this study, we present the discovery of a novel PDXK inhibitor, luteolin, through a high-throughput screening approach based on enzyme activity. Luteolin, a natural product, exhibits micromolar-level affinity for PDXK and effectively inhibits the enzyme's activity in vitro. Our crystal structures reveal that luteolin occupies the ATP binding pocket through hydrophobic interactions and a weak hydrogen bonding pattern, displaying reversible characteristics as confirmed by biochemical assays. Moreover, luteolin disrupts vitamin B6 metabolism by targeting PDXK, thereby inhibiting the proliferation of leukemia cells. This research introduces a novel screening method for identifying high-affinity and potent PDXK inhibitors and sheds light on clarification of the structural mechanism of PDXK-luteolin for subsequent structure optimization of inhibitors.